Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sac-TMT and Tagitanlimab in MSI-H/dMMR Advanced Gynecological Malignancies
NCT07738757Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan, tagitanlimab in endometrial cancer (EC), ovarian cancer, Cervical Cancer (CC), sponsored by Peking Union Medical College Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecantagitanlimab
03
Conditions
endometrial cancer (EC)ovarian cancerCervical Cancer (CC)
Beyond the preview
Go deeper on NCT07738757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07738757.